Trial Profile
A Phase 1/1b/2a, 3-Part, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 Monotherapy and in Combination With Venetoclax in Subjects With Relapsed or Refractory Haematologic Malignancies
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 28 Jul 2023
Price :
$35
*
At a glance
- Drugs AZD 5991 (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
- 15 Jun 2023 Results ( As of April 26, 2022, n=78) assessing the safety, tolerability, pharmacokinetics (PK), and antitumor activity ofAZD5991 monotherapy and in combination with venetoclax in patients (pts) with relapsed or refractory (R/R) hematologic malignancies presented at the 28th Congress of the European Haematology Association
- 25 Aug 2022 Status changed from suspended to discontinued.
- 14 Feb 2022 Planned End Date changed from 24 Jun 2024 to 4 Jul 2024.